SECTOR GAMMA AS recently filed their 13F report for the third quarter of 2022, which ended on 2022-09-30.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
FILIPSTAD BRYGGE 2 OSLO, Q8 0125
As of the latest 13F report, the guru’s equity portfolio contained 31 stocks valued at a total of $388.00Mil. The top holdings were GILD(14.04%), BIIB(7.58%), and INCY(7.19%).
According to GuruFocus data, these were SECTOR GAMMA AS’s top five trades of the quarter.
Merck & Co Inc
SECTOR GAMMA AS reduced their investment in NYSE:MRK by 161,179 shares. The trade had a 3.29% impact on the equity portfolio. During the quarter, the stock traded for an average price of $89.27.
On 11/09/2022, Merck & Co Inc traded for a price of $102.48 per share and a market cap of $260.21Bil. The stock has returned 27.41% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 9 out of 10.
In terms of valuation, Merck & Co Inc has a price-earnings ratio of 17.08, a price-book ratio of 5.85, a price-earnings-to-growth (PEG) ratio of 2.24, a EV-to-Ebitda ratio of 12.76 and a price-sales ratio of 4.43.
The price-to-GF Value ratio is 0.96, earning the stock a GF Value rank of 6.
Organon & Co
The guru sold out of their 356,089-share investment in NYSE:OGN. Previously, the stock had a 2.69% weight in the equity portfolio. Shares traded for an average price of $30.19 during the quarter.
On 11/09/2022, Organon & Co traded for a price of $23.92 per share and a market cap of $6.11Bil. The stock has returned -31.35% over the past year.
GuruFocus gives the company a financial strength rating of 3 out of 10 and a profitability rating of 6 out of 10.
In terms of valuation, Organon & Co has a price-earnings ratio of 7.83, a EV-to-Ebitda ratio of 7.60 and a price-sales ratio of 0.95.
CVS Health Corp
SECTOR GAMMA AS reduced their investment in NYSE:CVS by 124,668 shares. The trade had a 2.59% impact on the equity portfolio. During the quarter, the stock traded for an average price of $98.99.
On 11/09/2022, CVS Health Corp traded for a price of $100.08 per share and a market cap of $132.13Bil. The stock has returned 10.78% over the past year.
GuruFocus gives the company a financial strength rating of 5 out of 10 and a profitability rating of 8 out of 10.
In terms of valuation, CVS Health Corp has a price-earnings ratio of 20.32, a price-book ratio of 1.87, a price-earnings-to-growth (PEG) ratio of 3.91, a EV-to-Ebitda ratio of 17.17 and a price-sales ratio of 0.43.
The price-to-GF Value ratio is 1.08, earning the stock a GF Value rank of 3.
Baxter International Inc
The guru established a new position worth 169,028 shares in NYSE:BAX, giving the stock a 2.35% weight in the equity portfolio. Shares traded for an average price of $60.17 during the quarter.
On 11/09/2022, Baxter International Inc traded for a price of $52.18 per share and a market cap of $26.33Bil. The stock has returned -31.33% over the past year.
GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 8 out of 10.
In terms of valuation, Baxter International Inc has a price-book ratio of 4.76, a EV-to-Ebitda ratio of -68.33 and a price-sales ratio of 1.79.
The price-to-GF Value ratio is 0.50, earning the stock a GF Value rank of 8.
Vertex Pharmaceuticals Inc
The guru sold out of their 33,474-share investment in NAS:VRTX. Previously, the stock had a 2.11% weight in the equity portfolio. Shares traded for an average price of $287.72 during the quarter.
On 11/09/2022, Vertex Pharmaceuticals Inc traded for a price of $310.17 per share and a market cap of $79.62Bil. The stock has returned 62.32% over the past year.
GuruFocus gives the company a financial strength rating of 9 out of 10 and a profitability rating of 7 out of 10.
In terms of valuation, Vertex Pharmaceuticals Inc has a price-earnings ratio of 24.46, a price-book ratio of 6.11, a price-earnings-to-growth (PEG) ratio of 0.19, a EV-to-Ebitda ratio of 16.51 and a price-sales ratio of 9.22.
The price-to-GF Value ratio is 0.98, earning the stock a GF Value rank of 5.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
